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Quantitative real-time PCR (qPCR) has been proposed as a highly sensitive method for monitoring hemato-
poietic chimerism and may serve as a surrogate marker for the detection of minimal residual disease minimal
residual disease in myelodysplastic syndrome (MDS), until speciﬁc methods of detection become available.
Because a systematic comparison of the clinical utility of qPCR with the gold standard short tandem repeat
(STR)-PCR has not been reported, we retrospectively measured chimerism by qPCR in 54 children trans-
planted for MDS in a previous study. Results obtained by STR-PCR in the initial study served as comparison.
Because the detection limit of qPCR was sufﬁciently low to detect an autologous background, we deﬁned the
sample as mixed chimera if the proportion of recipient-derived cells exceeded .5%. The true positive rates
were 100% versus 80% (qPCR versus STR-PCR, not signiﬁcant), and mixed chimerism in most cases was
detected earlier by qPCR than by STR-PCR (median, 31 days) when chimerism was quantiﬁed concurrently in
peripheral blood and bone marrow. Both methods revealed a substantial rate of false positives (22.7% versus
13.6%, not signiﬁcant), indicating the importance of serial testing of chimerism to monitor its progression.
Finally, we propose criteria for monitoring chimerism in pediatric MDS with regard to the subtypes, speci-
mens, PCR method, and timing of sampling.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION the highly sensitive, accurate, and simple measurement of
Monitoring of chimerism of hematopoietic cells by con-
ventional short tandem repeat (STR)-PCR is the standard of
care for children with myelodysplastic syndrome (MDS) dur-
ing the post-transplant period. Since 2002, methods based on
quantitative real-time PCR (qPCR) have been developed foredgments on page 1924.
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ty for Blood and Marrow Transplantation.chimerism [1-18]. Recently, commercial qPCR-based assays
(eg, AlleleSEQR Chimerism Assay [Abbott Laboratories, Abbott
Park, IL], Mentype DIPscreen/DIPquant [Biotype Diagnostic
GmbH, Dresden, Germany]) have been promoted as simple
and sensitive methods to analyze chimerism [19]. The advent
of these newly developed approaches raises the question of
whether the commonly used gold standard method STR-PCR
is still state of the art. In 2007 we established a method of
sequence polymorphism-based qPCR that allowed measure-
ment of chimerism with a quantiﬁable limit (QL) lower than
10E-3 (0.1%) in almost all patients [5]. Highly sensitive
methods to monitor hematological remission may be of crit-
ical importance, particularly in advanced MDS, because this
Table 1
Patient Characteristics
Characteristic n
Diagnosis
MDS 54
Low-grade MDS 19
RCC 19
Advanced MDS 35
RAEB 12
RAEBT/MDR-AML 23
Medain age, yr (range) 11.3 (1.4-18.4)
Sex
Female 18
Male 36
Median follow-up after SCT,* yr (range)
Clinical 8.2 (0.3-14.0)
Chimerism 1.5 (0.2-7.2)
Chimerism analysis samples
Total 1033
PB 836
BM 197
Per patient, median (range) 21 (4-38)
PB 16 (2-34)
BM 3 (0-11)
Donor
MFD 16
MMFD 1
MUD 34
MMUD 3
Stem cell source
BM 24
PB 30
T cell depletion
Yes 7
No 47
Conditioning regimen
Busulfan-based regimen
Bu þ Cy (ATG) 4
Bu þ Cy þ Mel (ATG) 43
Bu þ Cy þ Thio (ATG/OKT3) 2
Nonebusulfan-based regimen
Thio þ Flu þ ATG 5
RAEB indicates refractory anemia with excess blasts; RAEBT, refractory
anemia with excess blasts in transformation; MDR-AML, myelodysplasia-
related acute myeloid leukemia; MFD, matched family donor; MMFD,
mismatched family donor; MMUD, mismatched unrelated donor; MUD,
matched unrelated donor; Bu, busulfan; Cy, cyclophosphamide; ATG,
antithymocyte globulin; Mel, melphalan; Thio, thiotepa; OKT3, orthoclone;
Flu, ﬂudarabine.
* Follow-up of patients alive and in CR independent of the type of
chimerism or immunological intervention.
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minimal residual disease (MRD). Furthermore, a second
grafting procedure is often not possible because of the rapid
progression of the underlying disease.
In this retrospective study, samples from a cohort of 54
children and adolescents with refractory cytopenia of
childhood (RCC) or advanced MDS, which had been analyzed
in our previous publication in 2005 [20], were studied for the
presence of hematopoietic chimerism by a qPCR-based
method [5]. The results obtained by STR-PCR in the previ-
ous study were reanalyzed and compared with the qPCR
analyses of the same samples. In addition to the evaluation in
2005, which was solely based on peripheral blood (PB)
samples, bone marrow (BM) cells were also included. The
analysis of the marrow compartment may increase the
sensitivity of the method with earlier detection of mixed
chimera (MC), if contaminationwith autologous stromal cells
is negligible. In the previous study, preemptive immuno-
therapy had been initiated in all patients with increasing MC
based on STR-PCR results and allowed 6 of 12 patients to
achieve complete chimera (CC) with sustained remission.
The present retrospective study of chimerism based on qPCR
was limited because of the nonrandomized design of the
previous study. Already in 2005, randomization of the
intervention for patients with increasing MC had been dis-
cussed but was deemed unethical because this approach
would have inevitably resulted in relapse or rejection in
patients of the control group [21].
The present study aimed to demonstrate that a highly
sensitive analysis of chimerism based on qPCR is feasible and
reliable in the care of post-transplant children with MDS.
However, in contrast to STR-PCR, qPCR is capable of detecting
autologous signals (AS), which are not clearly distinguishable
from the background. A low permanent background is ex-
pected because all organs carry autologous cells except cells of
the hematopoietic lineage. Therefore, it was of critical impor-
tance to deﬁne a threshold of detection for AS that allowed the
clinical diagnosis of MC. Based on this threshold, the desig-
nated limit of MC diagnosed by qPCR for the prediction of
relapse of disease was to be determined and compared with
the gold standard method STR-PCR. Because the sensitive
detection of chimerism by qPCR allowed the quantitation of
recipient-derived cells of at least .1%, our ﬁnal goal was to
evaluate whether this method could diagnose imminent
relapse represented by a state of MC sooner than the STR-PCR
method. Because early intervention for impending relapse is
crucial in high-risk patients, we also propose criteria for the
monitoring of chimerism in childrenwith MDS.METHODS
Patients and Samples
A German multicenter cohort of 54 children with MDS who underwent
allogeneic stem cell transplantation (allo-SCT) between May 1996 and
November 2003 was used for this retrospective analysis (Table 1) [20].
Patients were enrolled within trials of the European Working Group of MDS
in Childhood. The study was approved by the ethics committees of the
Universities of Tuebingen (No. 38/97) and Frankfurt/Main (No. 79/05) and
conducted according to the Declaration of Helsinki after obtaining informed
consent. MDS was classiﬁed according to World Health Organization
guidelines that included RCC as a provisional entity. Disease with refractory
anemia with excess blasts, refractory anemia with excess blasts in trans-
formation, and myelodysplasia-related acute myeloid leukemia were
collectively referred to as advanced MDS [22]. An update of the clinical data
was conducted for this comparative analysis at the European Working
Group of MDS in Childhood Coordinating Study Center on August 20, 2013.
In the previous study of chimerism by STR-PCR in 2005, surveillance of
chimerism was performed in PB weekly until day 100 and monthly there-
after [20]. In the present study, we reanalyzed chimerism in these PBsamples using qPCR and added an analysis of BM cells, which were obtained
regularly during the post-transplant care of patients with advanced MDS on
days 30, 60, 100, 200, and 365 and 18 months and in patients with RCC on
days 30 and 100. Chimerism by STR-PCR of these BM cells had already been
measured in 2005 but was not used for therapeutic decisions. These results
were included in the present comparative analysis.
Chimerism Assays
Analysis of chimerism by qPCR (TaqMan chemistry) was performed as
described byWillasch et al. [5]. Brieﬂy, 29 sequence polymorphism markers
were available for the initial marker screening. After primer selection,
standard ampliﬁcation curves generated from artiﬁcial chimeric mixtures of
DNA were used for quantitation of recipient-derived AS (QL  .1%) [5]. Pre-
vious chimerism results based on the semiquantitative STR-PCR method (QL
1% [10E-2]) were used for systematic comparison of both methods [20,23].
Classiﬁcation of Chimerism
The chimeric status of each patient was classiﬁed according to both
methods as shown in Table 2. When analyzed by STR-PCR, a patient was
classiﬁed as MC if an AS was 1% or higher in 2 consecutive samples, as low-
level MC (ll-MC) if an AS was equal to or below 1% in only 1 sample, and as
CC if no AS was detected at any time. When analyzed by qPCR, a patient was
classiﬁed as MC if an AS was equal to or exceeded .5%, as ll-MC if the AS
ranged between .1% and .5%, and as CC if no AS exceeded .1% at any time.
Table 2
Classiﬁcation of Chimerism*
State of Chimerism Real-time PCR (qPCR) STR-PCR
CC AS < .1% No AS
ll-MC .1%  AS < .5% AS  1%y
MC AS  .5% AS  1%z
Decreasing MC MC at days 20-40 with decrease in AS
* Chimerism was classiﬁed in 4 categories according to the detection of
recipient-derived AS. Because early detection of imminent relapse was
sought by a highly sensitive qPCR method, low thresholds of detection were
assessed to deﬁne mixed chimerism: AS .1% deﬁned ll-MC and .5%
deﬁned MC. For STR-PCR, detection of an AS 1% at a single time point
deﬁned ll-MC, whereas the detection of an AS of 1% or higher in 2 consec-
utive samples deﬁned MC. Decreasing MC was deﬁned as the detection of
MC between days 20 and 40 after allo-SCT followed by decreasing AS in
subsequent consecutive samples.
y In 1 sample only.
z In 2 consecutive samples.
A.M. Willasch et al. / Biol Blood Marrow Transplant 20 (2014) 1918e19251920Decreasing MCwas deﬁned as a state of MC early after transplantation (days
20 to 40), with a subsequent decrease in the AS during follow-up.
Statistical Analysis
Fisher’s exact test was used for the analysis of 2  2 contingency tables.
P < .05 was considered to be statistically signiﬁcant. The date of the analysis
was August 20, 2013.
Sensitivity and speciﬁcity
A positive diagnostic test result, here a state of MC, can be either a true
or false positive. The sensitivity measured the proportion of test-positive
patients correctly identiﬁed as such. The false-positive rate measured the
proportion of test positives incorrectly identiﬁed as such. Relapse or a state
after immunotherapy (¼ imminent relapse) was intended to be predicted by
the diagnosis of MC.
A negative diagnostic test result, here a state of CC or ll-MC, can be either
a true or false negative. The speciﬁcity measured the proportion of test-
negative patients correctly identiﬁed as such. The false-negative rate
measured the proportion of test negatives incorrectly identiﬁed as such.
Complete remission (CR) or transplant-related mortality while being in CR
were intended to be predicted by the diagnosis of CC or ll-MC.
Predictive value
The positive predictive value (PPV) measured the proportion of test-
positive patients correctly identiﬁed as such among all test-positive patients.
The negative predictive value (NPV) measured the proportion of test-negative
patients correctly identiﬁed as such among all test-negative patients.
RESULTS
Patients and Samples
Chimerism analysis by qPCRwas performed in 54 patients
(RCC, n ¼ 19; advanced MDS, n ¼ 35; Table 1). The median
follow-up time for concurrent monitoring of chimerism by
qPCR and STR-PCR was 1.5 years (range, .2 to 7.2). Altogether,
1033 samples (PB, n ¼ 836; BM, n ¼ 197) were analyzed. The
median number of follow-up samples per patient was 16 for
PB (range, 2 to 34), 3 for BM (range, 0 to 11), and 21 for
combined PBeBM (range, 4 to 38). To evaluate the potential
beneﬁt of BM analyses, the state of chimerism of each patient
was determined for PB samples alone (“PB-alone”) and for
the combination of PB and BM (“combined-PBeBM”). For the
latter, the detection of AS in PB and BMwas regarded to be of
equal importance for the diagnosis of MC (Table 2).
Patients with MC
There were 29 of 54 patients (54%) with MC diagnosed by
either chimerism method using PB-alone or combined
PBeBM (Table 3). Sixteen of 29 patients had advanced MDS.
The highest proportion of patients with MC within this
cohort was diagnosed by qPCR in combined PBeBM (14/16,
88%), whereas the lowest proportion (8/16, 50%) wasdetected by STR-PCR in PB-alone. Within the RCC cohort, 13
patients had MC, which was most frequently detected by
qPCR in combined PBeBM (6/13, 46%). qPCR in PB-alone as
well as STR-PCR (in PB-alone and combined PBeBM) diag-
nosed MC in the same number of cases (3/13, 23%). Because
all patients with RCC remained in CR, these results indicate
that both chimerism by qPCR and analysis in BM cells
introduced the highest risk for false-positive results (see
detailed analysis below). Obviously, these host cells, repre-
sented by a state of MC, did not expand but were eradicated
by the donor graft later on.
If MC occurs soon after transplantation, it is impossible to
predict whether patients will develop decreasing MC, sub-
sequently achieve CC, or maintain MC during follow-up and
eventually relapse. Therefore, the ﬁrst MC sample of all MC
patients was analyzed with regard to the PCR method of
detection and the source of material (Table 3, column 4).
Evaluating PB-alone, the ﬁrst MC was demonstrated in 12 of
22 patients (54%) by qPCR, in 7 of 22 (32%) by STR-PCR, and in
3 of 22 (14%) concurrently by both methods (not signiﬁcant).
Studying combined PBeBM, theﬁrstMCwas noted in 19 of 29
patients (65%) by qPCR, in 6 of 29 patients (21%) by STR-PCR,
and in 4 of 29 (14%) by both methods concurrently. Thus,
studying combined PBeBM, the qPCR method allowed early
detection of MC more frequently than STR-PCR (P ¼ .012).
Patients with CC and ll-MC
There were 25 of 54 patients (46%) with CC or ll-MC
diagnosed by both PCR methods in PB-alone or combined
PBeBM (Table 4). None of these patients relapsed or rejected
the stem cell graft. Nineteen patients remained in long-term
CR, whereas 6 patients experienced transplant-related mor-
tality while in remission. The highest proportion of patients
with ll-MC within the advanced MDS cohort was diagnosed
by qPCR of combined PBeBM (8/19, 42%), whereas the lowest
proportion (3/19, 16%) was detected by STR-PCR of PB-alone
and combined PBeBM. Within the RCC cohort, ll-MC was
most frequently detected by qPCR of PB-alone and combined
PBeBM (3/6, 50%) and the lowest proportion (1/6, 17%) by
STR-PCR of the same types of specimens. qPCR most
frequently detected low-level recipient-derived AS.
Sensitivity, Speciﬁcity, and Predictive Value
In PB-alone, sensitivity and false-positive rate were 70.0%
and 9.1% for STR-PCR and 80.0% and 15.9% for qPCR, respec-
tively (Table 5). Inclusion of BM samples led to a sensitivity of
100.0% and 22.7% of false positives by qPCR, whereas the STR-
PCR method reached a sensitivity of 80.0% and 13.6% of false
positives (Table 5). Because of the limited number of relapsed
patients in this cohort, these differences did not reach sta-
tistical signiﬁcance. However, a trend toward higher sensi-
tivity and higher false-positive rate by qPCR was observed,
which may be accounted for by its lower QL.
In PB-alone, speciﬁcity and false-negative rate were 90.9%
and 30.0% by STR-PCR and 84.1% and 20.0% by qPCR,
respectively (Table 5). If BM samples were included, STR-PCR
reached a speciﬁcity of 86.4% and 20.0% of false negatives,
whereas qPCR reached a speciﬁcity of 77.3% and 0.0% false
negatives, respectively (Table 5). These differences did not
reach statistical signiﬁcance. However, there was a trend
toward higher speciﬁcity and higher false-negative rate by
STR-PCR, which may be accounted for by its limited quanti-
ﬁable threshold.
The PPV of STR-PCR was 63.6% (7/11) in PB-alone and
57.1% (8/14) in combined PBeBM. qPCR achieved a PPV of
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Table 4
Patients with CC or ll-MC
Diagnosis STR-PCR qPCR Follow-Up
(day)
Outcome
Chimerism
Classiﬁcation
Onset of ll-MC
(day)
Chimerism
Classiﬁcation
Onset of ll-MC
(day)
PB PBeBM PB PBeBM PB PBeBM PB PBeBM
Advanced MDS
RAEB ll-MC ll-MC 48 48 CC CC - - 62 CR
RAEB CC CC - - CC CC - - 105 CR
RAEBT/AML CC CC - - ll-MC ll-MC 229 229 229 CR
RAEB CC CC - - ll-MC ll-MC 69 48 321 CR
RAEBT/AML CC CC - - ll-MC ll-MC 129 28 364 CR
RAEBT/AML CC CC ll-MC ll-MC 48 48 422 CR
RAEBT/AML CC CC - - ll-MC ll-MC 31 31 473 CR
RAEBT/AML CC CC - - CC CC - - 551 CR
RAEB ll-MC ll-MC 82 82 ll-MC ll-MC 82 82 669 CR
RAEBT/AML CC CC - - CC ll-MC - 30 756 CR
RAEB CC CC - - CC CC - - 1090 CR
RAEB ll-MC ll-MC 517 61 CC CC - - 1680 CR
RAEBT/AML CC CC - - ll-MC ll-MC 28 28 2346 CR
RAEBT/AML CC CC - - CC CC - - 2635 CR
RAEB CC CC - - CC CC - - 58 TRM
RAEBT/AML CC CC - - CC CC - - 58 TRM
RAEBT/AML CC CC - - CC CC - - 128 TRM
RAEBT/AML CC CC - - CC CC - - 203 TRM
RAEB CC CC - - CC CC - - 337 TRM
Low-grade MDS
RCC CC CC - - CC CC - - 185 CR
RCC CC CC - - ll-MC ll-MC 52 52 236 CR
RCC CC CC - - CC CC - - 365 CR
RCC CC CC - - ll-MC ll-MC 49 49 372 CR
RCC ll-MC ll-MC 20 20 ll-MC ll-MC 34 34 1119 CR
RCC CC CC - - CC CC - - 60 TRM
This table includes patients with CC or ll-MC (25/54) detected by either method (STR-PCR or qPCR) in PB-alone and combined PBeBM. Patients were stratiﬁed by
type of MDS and outcome. In patients with advancedMDS, analyses of PB-alone and combined PBeBM detected CC in 16 of 19 (84%) and ll-MC in 3 of 19 (16%) by
STR-PCR. Analyses of PB-alone detected CC in 12 of 19 (63%) and ll-MC in 7 of 19 (37%) by qPCR. Analyses of combined PBeBM detected CC in 11 of 19 (58%) and
ll-MC in 8 of 19 (42%) by qPCR. In patients with RCC, analyses of PB-alone as well as combined PBeBM detected CC in 5 of 6 (83%) and ll-MC in 1 of 6 (17%) by STR-
PCR whereas qPCR found CC in 3 of 6 (50%) and ll-MC in 3 of 6 (50%) patients in the same types of specimens.
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mens (not signiﬁcant). These results were in agreement with
the substantial rate of false positives of PCR-based chimerism
methods as mentioned above.
The NPV was at least 93.0% for both methods. Speciﬁcally,
the NPV of STR-PCR was 93.0% (40/43) for PB-alone and
95.0% (38/40) for combined PBeBM, whereas NPV of qPCR
was 94.9% (37/39) for PB-alone and 100.0% (34/34) in com-
bined PBeBM (not signiﬁcant). Consequently, if qPCR diag-
nosed a patient to be a CC or ll-MC in combined PBeBM, the
likelihood of subsequent relapse was .0%.
Time-Dependent Diagnosis of MC
The early diagnosis of impending relapse could expand
the window for intervention and prevent overt relapse of the
disease. For the most part, lowering the QL could permit
earlier detection of MC, allowing a decision to be made about
additional immunotherapy. The time-dependent detection
of MC is shown in Table 6. In PB-alone, MC was detected
concurrently by both methods in 4 of 10 patients (40%) at a
median of day 144 post-transplant (range, 39 to 1273;
Table 6). MC was detected sooner by qPCR in 4 of 10 patients
(40%) and by STR-PCR in 2 of 10 patients (20%) (not signiﬁ-
cant). In combined PBeBM,MCwas detected concurrently by
both methods in 4 of 15 patients (27%) at a median of day 30
post-transplant (range, 26 to 236; Table 6). MC was detected
signiﬁcantly earlier by qPCR in 9 of 15 patients (60%) than by
STR-PCR in only 2 of 15 patients (13%) (P ¼ .02). Conse-
quently, if BM samples were included, qPCR allowed an
earlier detection of MC more frequent than STR-PCR.DISCUSSION
The use of qPCR-based methods is widespread in diag-
nostic health care. In the ﬁeld of chimerism, conventional STR-
PCR is commonly used as the gold standard method to
distinguish recipient-from donor-derived hematopoiesis.
Recently, commercial qPCR-based assays have been promoted
asalternative, sensitive, and rapidmethods forpost-transplant
chimerismmonitoring [19]. In 2007, we established our qPCR-
based systemfor sensitive analysis of chimerismwithaQLof at
least .1%,whichwas1 log-unit lower than that achievedwith
STR-PCR [5].
Studies that systematically evaluated the clinical impact
of chimerism monitoring by qPCR in comparison with STR-
PCR are lacking. In 2005, we reported on the importance of
STR-PCRebased chimerism in PB samples for the detection of
imminent relapse in children with MDS as well as on the
efﬁcacy of chimerism-based preemptive immunotherapy in
these patients [20]. The samples from 54 patients of this
cohort were used to evaluate the performance of qPCR-based
chimerism analysis. Analysis of chimerism in BM samples
could potentially increase the sensitivity of the method. On
the other hand, potential contamination with autologous
stromal cells may reduce the speciﬁcity and increase the
number of false-positive results. To study this question, the
present comparative analysis between STR-PCR and qPCR
included BM samples, whereas the previous study was solely
based on PB samples. Currently, qPCR is the only method that
can detect .05% minor component in a mixed DNA sample
[1,5]. However, lowering the QL could result in the detection
of AS in almost every sample. The challenge is to deﬁne a
Table 5
Sensitivity and Speciﬁcity of STR-PCR versus qPCR in Detecting Chimerism
n Analyses of PB (n ¼ 54)
STR-PCR qPCR STR-PCR qPCR
n % n % n % n %
Relapse or status post IT Sensitivity (true-positive rate) False-negative rate
10 7 70.0 8 80.0 3 30.0 2 20.0
CR or TRM Speciﬁcity (true-negative rate) False-positive rate
44 40 90.9 37 84.1 4 9.1 7 15.9
n Analyses of Combined PB and BM (n ¼ 54)
STR-PCR qPCR STR-PCR qPCR
n % n % n % n %
Relapse or status post IT Sensitivity (true-positive rate) False-negative rate
10 8 80.0 10 100.0 2 20.0 0 0.0
CR or TRM Speciﬁcity (true-negative rate) False-positive rate
44 38 86.4 34 77.3 6 13.6 10 22.7
Differences in percentages between STR-PCR and qPCR were not statistically signiﬁcant (Fisher’s exact test).
The sensitivity of a diagnostic method measured the proportion of test positive patients that were correctly identiﬁed as such. The diagnosis of MC was deﬁned
as test positive. Subsequent relapse or status post IT (¼ imminent relapse) were intended to be predicted by the diagnosis of MC by using 1 of the PCR methods.
By analogy, the false-negative rate measured the proportion of test-negative patients incorrectly identiﬁed as such. The speciﬁcity of a diagnostic method
measured the proportion of test-negative patients correctly identiﬁed as such. The diagnosis of CC or ll-MC was deﬁned as test negative. CR or TRM while being
classiﬁed CR were intended to be predicted by the diagnosis of CC or ll-MC. By analogy, the false-positive rate measured the proportion of test-positive patients
incorrectly identiﬁed as such. For the analyses of PB-alone, imminent relapse was diagnosed in 7 of 10 (STR-PCR) and 8 of 10 (qPCR), whereas both methods
maintained a high speciﬁcity of 90.9% (STR-PCR) and 84.1% (qPCR). For the analyses of combined PBeBM, imminent relapse was diagnosed in 8 of 10 (STR-PCR)
and 10 of 10 (qPCR). Consequently, the speciﬁcity dropped to 86.4% (STR-PCR) and 77.3% (qPCR). The desired identiﬁcation of all patients with imminent relapse
(10/10) by qPCR was hindered by the detection of 10 of 44 (22.7%) false positives. Here, 50% of patients had a true and 50% of patients had a false MC diagnosis.
Differences in percentages did not reach statistical signiﬁcance. However, a trend toward higher sensitivity and lower speciﬁcity of qPCR compared with STR-
PCR existed due to the lower QL of qPCR.
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qPCR. In the present study, samples were classiﬁed as MC if
the AS was .5%. Chimerism analyses aim to detect immi-
nent relapse early to allow timely intervention. Therefore,
our threshold for the deﬁnition of MC for both methods was
relatively stringent. Such a policy could potentially result in
an increased proportion of MC results for patients in remis-
sion. This consideration was conﬁrmed by the relatively
low PPV for both chimerism methods (maximum PPV, 63.6%
by STR-PCR). On the other hand, the NPV was 93.0% for PB-
alone (STR-PCR) and 100.0% for combined PBeBM (qPCR),Table 6
Time-Dependent Detection of MC: STR-PCR versus qPCR
Chimerism Method No. of Patients Median No. of
Days (range)
Sample source: PB
STR-PCR earlier 2/10 (20%)* 35 (7-63)y
qPCR earlier 4/10 (40%)* 65 (28-161)y
STR-PCR, qPCR concurrently 4/10 (40%) 144 (39-1273)z
Sample source: PB and BM
STR-PCR earlier 2/15 (13%)x 71 (7-135)y
qPCR earlier 9/15 (60%)x 31 (3-831)y
STR-PCR, qPCR concurrently 4/15 (27%) 30 (26-236)z
In contrast to Table 3, this analysis included patients diagnosed with MC by
both chimerism methods. For the time-dependent detection of MC in PB-
alone, MC was diagnosed by both methods in 10 of 23 patients (43%). In 4
of 10 patients, a state of MCwas diagnosed concurrently by both methods at
day 144 (median), ranging from day 39 to 1273. qPCR diagnosed MC sooner
in 4 of 10 patients, whereas STR-PCR diagnosed MC sooner in 2 of 10
patients. For the time-dependent detection of MC in combined PBeBM, MC
was diagnosed by both methods in 15 of 29 patients (52%). In 4 of 15 cases, a
state of MC was diagnosed concurrently by both methods at day 30
(median), ranging from day 26 to 236. Interestingly, qPCR diagnosed MC
sooner more frequently than STR-PCR (9/15 vs. 2/15 cases). This difference
was statistically signiﬁcant (P ¼ .02).
* Not signiﬁcant.
y Days, MC was detected sooner.
z Days post transplantation.
x Signiﬁcant (P ¼ .02, Fisher’s exact test).indicating the probability of relapse in patients with CC or ll-
MC by both methods was extremely low. Both methods were
capable of monitoring chimerism reliably and demonstrated
speciﬁc strengths and weaknesses, discussed in some detail
below.Advantages of qPCR
Highly sensitive methods for monitoring of MRD are not
available for most MDS patients. Chimerism by qPCR may
serve as surrogate marker for MRD in advanced MDS until
speciﬁc methods to detect residual disease are available. The
dynamic range covers 3 log-units, and results are normal-
ized to control PCR. Because of the direct ampliﬁcation of the
haplotype to be analyzed, the quantitative results are
reproducible and precise. Quantitation is possible below 1%
of the minor DNA haplotype, where STR-PCR merely yields
reproducible results [1,5].
The detection range of qPCR was low enough to ﬁnd an
autologous background, which allowed the deﬁnition of a
threshold, that matched the clinical endpoint. Using a
threshold of .5%, wewere capable of diagnosing a state of MC
(imminent relapse) in all patients, who subsequently
relapsed. This threshold was close to the detection limit of
STR-PCR, and because of the low relapse rate in this study,
differences in sensitivity between both methods did not
reach statistical signiﬁcance. But analysis by qPCR in com-
bined PBeBM allowed early detection of MC signiﬁcantly
more frequently compared with STR-PCR. Therefore,
chimerism by qPCR could broaden the therapeutic window
for intervention in patients with imminent relapse. More-
over, this method combined PCR with the process of quan-
titation in a single procedure. This avoids postreaction
manipulation, saves time, and minimizes the risk of labora-
tory contamination of the PCR products [5,19]. Our ﬁndings
are not necessarily transferable to commercial qPCR-
based chimerism assays. Kletzel et al. [19] compared the
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VNTR-PCR and found complete correlation between the 2
methods. However, validation of the clinical impact was not
the focus of that study. The clinical importance needs to be
evaluated for these commercial assays.
Advantages of STR-PCR
Within this standard chimerism monitoring method,
conventional PCR followed by quantitation of PCR products
by capillary electrophoresis provided a QL of 1%. A major
advantage is the simultaneous monitoring of 2 parameters:
the peak height, which provides information of the relative
portion of the major and minor population within a sample,
and the genotype (STR pattern), which allows validation of
the sample identity [23].
In this study, STR-PCR detected imminent relapse by MC
in 8 of 10 patients (combined PBeBM) because of the limited
quantiﬁable threshold. Nevertheless, the sensitivity of STR-
PCR did not signiﬁcantly differ from that of qPCR. The
false-positive rate (4/44, 9.1%) of STR-PCR for PB-alone was
the lowest in this study, underlying its high speciﬁcity.
Highly sensitive chimerism by qPCR enabled the early
detection of an imminent relapse associated with MC. Inter-
estingly, STR-PCR detectedMC earlier comparedwith qPCR in
2 of 15 patients despite its limited quantiﬁable threshold. This
differencewas supported by the fact that patientswere rarely
diagnosed to be MC by STR-PCR but were diagnosed as CC by
qPCR. Because qPCR measures the copy number of genes
within a sample, this method strongly depends on the
quantity of DNA available for the PCR. If only a low quantity
could be isolated (eg, in cell subpopulations), the sensitivity
could be limited [12]. In contrast, the competitive approach of
STR-PCR, which analyzes the proportions of recipient and
donor alleles, is not subject to this restriction. That may help
to explain the difference mentioned above.
Disadvantages of qPCR
Increasing the sensitivity of a diagnostic method mainly
augments the risk of decreasing the speciﬁcity and increasing
the false-positive rate. Thus, it is of critical importance that
the detection of AS by chimerism analysis is not equatedwith
MRD. The presence of AS detected by STR-PCR can diminish
the graft-versus-tumor effect and facilitate the recurrence of
residual disease [24,25]. This, however, may not necessarily
be true when a low amount of AS is detected by a highly
sensitive qPCR.
In this study, 2 approaches, analysis by qPCR and analysis
in BM samples, increased the sensitivity of chimerism anal-
ysis but also led to a substantial rate of false positives, which
was as high as 10 of 44 (22.7%). Detection of MC by a highly
sensitive method may trigger a therapeutic intervention in a
patient who would never relapse. Obviously, such an inter-
vention would expose that patient to an unnecessary risk of
inducing graft-versus-host disease. Consequently, the desir-
able sensitivity of 100% of qPCR coincidently included the
method’s most serious disadvantage, which was a substan-
tial rate of false positives. However, it must be stressed that
false positives were also detected by STR-PCR (13.6%). This
observation emphasized the importance of serial analysis of
chimerism tomonitor its progression. In contrast to STR-PCR,
qPCR did not include genotyping as discussed above.
Disadvantages of STR-PCR
In STR-PCR the quantiﬁable threshold and range are
limited for technical reasons. The dynamic range representedby linear scaled measurement covers only 2 log-units. The
maximal performance is reachable only when the running
parameters are optimized [23]. Consequently, imminent
relapse was not detected by STR-PCR in every case before
frank hematological relapse in previous studies [25]. In
addition, residual malignant cells might proliferate enor-
mously within days, making it impossible for chimerism
methods to diagnose imminent relapse before frank relapse
is evident. These considerations were illustrated by the
present study: Imminent relapse was diagnosed by STR-PCR
in only 7 of 10 patients (PB-alone). Moreover, MC was less
frequently detected early by STR-PCR compared with qPCR.
CONCLUSION
We present, for the ﬁrst time, a comparative analysis of
the clinical impact of qPCR and STR-PCR in a cohort of chil-
dren with MDS and detected a clinically relevant proportion
of AS (.5%) by qPCR for the diagnosis of MC. Chimerism
monitoring of BM cells, in addition to analyses in PB samples,
could further increase the sensitivity of the method. qPCR-
based chimerism analysis may be of particular importance
as a surrogate marker for MRD in patients with advanced
MDS. However, this sensitive assay was not necessarily
superior compared with STR-PCR. Both methods were
capable of reliable characterization of chimerism with uni-
que strengths and weaknesses. Regardless of the method
used, this study demonstrated the importance of serial and
frequent analyses to monitor the progression of chimerism.
Proposal for Chimerism Monitoring of MDS in Childhood
In low-grade MDS (RCC), the main goal of chimerism
analysis is to monitor engraftment, graft rejection, or graft
failure. Therefore, chimerism should be analyzed with high
speciﬁcity to obtain a low false-positive rate. Currently, we
recommend monitoring chimerism by STR-PCR in PB at days
30, 60, 100, and 180. If MC is diagnosed, chimerism should be
analyzed weekly to determine its progression. In general,
immunotherapy is not indicated because second grafting
procedures can be performed in the absence of leukemic
cells (“do-no-harm” policy).
In advanced MDS, characterized by excess blasts in the
BM [22], early detection of imminent relapse is of particular
interest and close monitoring of chimerism is recommended.
In the absence of controlled clinical trials studying the
impact of the frequency of chimerism analyses, we recom-
mend chimerism studies in PB every other week between
days 15 and 200 and monthly thereafter for the ﬁrst year of
therapy. The decision for immunotherapy based on a diag-
nosis of MC should be taken according to the respective trial,
inwhich the patient is enrolled. Based on our data, we do not
recommend serial analysis in BM samples. However, if a BM
specimen is needed, chimerism can be analyzed. In general,
we propose the application of STR-PCR. The highly sensitive
qPCR can be of particular importance when a high sensitivity
is required. The potential beneﬁt of qPCR still needs to be
demonstrated in prospective clinical trials.
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